Gemeinsamer Bundesausschuss

Resolution

of the Federal Joint Committee (G-BA) on the Suspension of the Consultation Procedure under Section 35a paragraph 3b SGB V: Glofitamab (relapsed or refractory diffuse large B-cell lymphoma); requirement of routine practice data collection and evaluations

of 5 June 2025

At their session on 5 June 2025, the Federal Joint Committee (G-BA) decided the following:

I. The consultation procedure on the requirement of routine practice data collection and evaluations according to Section 35a paragraph 3b SGB V for the active ingredient glofitamab for the treatment of

"Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy, who are ineligible for CAR T-cell therapy and stem cell transplantation"

is suspended.

II. The resolution will enter into force on the day of its publication on the website of the G-BA on 5 June 2025.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 5 June 2025

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken